{"url_path":"/sec/zura/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1855644/0001855644-26-000007-index.html","accession_number":"0001855644-26-000007","cik":"0001855644","ticker":"ZURA","issuer_name":"Zura Bio Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855644/0001855644-26-000007-index.html","primary_entity_key":"0001855644","primary_entity_name":"Zura Bio Ltd"},"word_count":161,"has_tables":true,"body_markdown":"Item 2.02.    Results of Operations and Financial Condition.\n\nOn August 11, 2026, Zura Bio Limited (the “Company”) issued a press release announcing its second quarter 2026 financial results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.\n\nThe information furnished under this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing."}